GERN — GERON CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886744 ·
Last close
$1.29
Market Cap
$827.56M
52W High
$1.73
52W Low
$1.08
ADV30
11,505,912
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 51,837,000 | 50,145,000 | -236,000 | -3,642,000 | 534,120,000 | 68,895,000 | 305,012,000 |
| Dec 2025 | 48,015,000 | 46,709,000 | -8,508,000 | -28,862,000 | 570,540,000 | 77,560,000 | 344,668,000 |
| Sep 2025 | 47,227,000 | 46,184,000 | -13,887,000 | -18,428,000 | 567,382,000 | 78,117,000 | 318,675,000 |
| Jun 2025 | 49,036,000 | 47,846,000 | -12,454,000 | -16,375,000 | 555,198,000 | 77,734,000 | 295,667,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-111,037,000
Investing CF
$107,247,000
Financing CF
$2,267,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,855,841,000
Inventory
$116,636,000
Receivables
$39,226,000
ST Investments
$280,359,000
EBIT TTM
$-50,843,000
Pretax Income TTM
$-83,500,000
Interest Exp TTM
$32,657,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$196,115,008
EBITDA
$-34,608,000
Free Cash Flow
$-92,136,624
Enterprise Value
$669,303,104
Total Cash
$312,400,992
Total Debt
$122,066,000
Shares Out
641,520,974
Trailing EPS
$-0.11
Book Value
$0.36
ROE
-27.1%
ROA
-4.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 183,881,000 | -51,553,000 | -83,500,000 | 570,540,000 | 344,668,000 | — | -111,037,000 |
| Dec 2024 | 76,994,000 | -173,732,000 | -174,572,000 | 593,781,000 | 313,461,000 | — | -218,618,000 |
| Dec 2023 | 237,000 | -193,944,000 | -184,127,000 | 394,076,000 | 146,127,000 | — | -167,743,000 |
| Dec 2022 | 596,000 | -138,550,000 | -141,901,000 | 190,575,000 | 110,577,000 | — | -127,379,000 |
TTM Snapshot
Revenues TTM
$28,271,000
NetIncome TTM
$-26,447,000
OpCashFlow TTM
$0
Assets (Latest)
$593,781,000
Forward EPS
$0.06
Max Pain — expiry 2027-01-15
max pain strike: $1.00 · spot: $1.29 · call oi: 26,409 · put oi: 14,053
Expected Move to 2027-01-15:
±$0.70
(54.26%) —
implied range
$0.59 –
$1.99
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANNX | Annexon, Inc. | $834.78M | $5.09 | — |
| IVEVF | Inventiva S.A. | $848.03M | $3.59 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $806.33M | $0.77 | — |
| KURA | Kura Oncology, Inc. | $799.86M | $9.01 | — |
| OMER | OMEROS CORP | $856.92M | $11.84 | — |
News headlines (Yahoo Finance, 1h cache)
Regeneron (REGN) Q2 Earnings and Revenues Top Estimates
2026-07-30 12:05 · Yahoo
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-22 20:01 · Yahoo
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
2026-07-22 11:00 · Yahoo
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
2026-07-15 13:00 · Yahoo
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-14 20:26 · Yahoo
Geron (GERN) Grants Inducement Stock Options to New Employees
2026-07-14 10:34 · Yahoo
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
2026-07-13 12:00 · Yahoo
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
2026-06-29 10:46 · Yahoo
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
2026-06-04 13:35 · Yahoo
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-01 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.